Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan

Toshihiro Nishizawa; Hidekazu Suzuki; Kumiko Kurabayashi; Tatsuhiro Masaoka; Hiroe Muraoka; Mikiji Mori; Eisuke Iwasaki; Intetsu Kobayashi; Toshifumi Hibi

doi:10.1128/AAC.50.4.1538-1540.2006

Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan

Antimicrob Agents Chemother. 2006 Apr;50(4):1538-40. doi: 10.1128/AAC.50.4.1538-1540.2006.

Authors

Toshihiro Nishizawa¹, Hidekazu Suzuki, Kumiko Kurabayashi, Tatsuhiro Masaoka, Hiroe Muraoka, Mikiji Mori, Eisuke Iwasaki, Intetsu Kobayashi, Toshifumi Hibi

Affiliation

¹ Department of Internal Medicine, Keio University School of Medicine, and Department of Gastroenterology, Kitasato Institute Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Abstract

A high resistance rate (47.9%) to gatifloxacin (GAT; 8-methoxy fluoroquinolone) in Helicobacter pylori (H. pylori) strains from 48 Japanese patients is observed after unsuccessful H. pylori eradication. A significant association between MICs for GAT equal to or above 1 microg/ml and mutations of the gyrA gene of H. pylori was demonstrated.

MeSH terms

Anti-Infective Agents / pharmacology*
DNA Gyrase / genetics*
Drug Resistance, Bacterial
Female
Fluoroquinolones / pharmacology*
Gatifloxacin
Helicobacter pylori / drug effects*
Helicobacter pylori / genetics
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Mutation*

Substances

Anti-Infective Agents
Fluoroquinolones
DNA Gyrase
Gatifloxacin